Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 136 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: mCC Clear all
Completed Phase 1 Interventional

A Study of Lung Clearance After Hypertonic Saline Delivery Using the tPAD Device

NCT02141191
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
inhaled hypertonic saline (7%)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 18, 2026, 5:13 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation

NCT07818564
View directory record Official record
Conditions
Phase I
Interventions
Psilocybin (Usona Institute), Inactive Placebo (Usona Institute)
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 18, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of R406 in Healthy Volunteers When Given 100mg and 150 mg of Fostamatinib

NCT01645085
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MCC-based 13% drug loaded tablets, Mannitol-based 38% drug-loaded tablet
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Oct 18, 2026, 5:13 AM EDT
Completed Not applicable Interventional

Caremap: A Digital Personal Health Record for Complex Care Coordination

NCT05056493
View directory record Official record
Conditions
Children/Youth With Special Healthcare Needs, Adults With Multiple Chronic Conditions
Interventions
Caremap app
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 18, 2026, 5:13 AM EDT
Not listed Phase 1Phase 2 Interventional

Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

NCT03787602
View directory record Official record
Conditions
Merkel Cell Carcinoma
Interventions
KRT-232, Avelumab
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
14
States / cities
Aurora, Colorado • Miami, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 18, 2026, 5:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

NCT00934856
View directory record Official record
Conditions
Breast Cancer
Interventions
Docetaxel, Pertuzumab, Trastuzumab emtansine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Charlotte, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 18, 2026, 5:13 AM EDT
Completed Phase 4 Interventional Results available

Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis

NCT05740618
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Mannitol Inhalant Product
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 18, 2026, 5:13 AM EDT
Completed No phase listed Observational Results available

A Study to Explore the Utility of Fractional Exhaled Nitric Oxide (FeNO) Compared With Methacholine Challenge (MCC) Testing in the Assessment of Patients With Suspected But Undiagnosed Asthma

NCT01648920
View directory record Official record
Conditions
Asthma
Interventions
NIOX MINO® Instrument (09-1100)
Device
Lead sponsor
Aerocrine AB
Industry
Eligibility
7 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
8
States / cities
Blue Bell, Pennsylvania • Collegeville, Pennsylvania • Doylestown, Pennsylvania + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 18, 2026, 5:13 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Dietary Supplementation on Body Fat Composition

NCT06296251
View directory record Official record
Conditions
Dyslipidemias, Pre-diabetes
Interventions
Placebo treatment, Plant derived phenolics
Other · Dietary Supplement
Lead sponsor
Brightseed
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 18, 2026, 5:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting

NCT01989156
View directory record Official record
Conditions
Smoking
Interventions
THS 2.2 Menthol (mTHS 2.2), Menthol Conventional Cigarette (mCC), Smoking Abstinence (SA)
Other
Lead sponsor
Philip Morris Products S.A.
Industry
Eligibility
22 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 18, 2026, 5:13 AM EDT
Completed Not applicable Interventional Results available

Effect of Hypertonic Saline on Mucus Clearance in Children Ages 5-12 With Cystic Fibrosis

NCT01031706
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Hypertonic Saline, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
5 Years to 12 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 18, 2026, 5:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Absorptive Clearance in the Cystic Fibrosis Airway

NCT00541190
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 18, 2026, 5:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Mucociliary Clearance in Healthy Subjects: Comparison of Levalbuterol and Racemic Albuterol

NCT00325767
View directory record Official record
Conditions
Mucociliary Clearance
Interventions
nebulized albuterol (2.5 mg/3ml/dose), nebulized levalbuterol (1.25 mg/3ml/dose), nebulized placebo (3ml/dose)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 15, 2006 · Synced Oct 18, 2026, 5:13 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Outreach Core Activities

NCT05832177
View directory record Official record
Conditions
Cancer Education, Spanish Language Cancer Education
Interventions
Cancer CientoUno (101) program, Latinos y el cáncer/Hablemos de cáncer (Translation in English: Latinos and Cancer/Let's Talk About Cancer), ¡Salud! Serie de Charlas (Translation in English: Health! Talk Series), Community/Researcher Forum: El Puente (Translation in English: The Bridge)., Lunch and Learn Updated Recommendations Series., Community Engagement (CE) Training Program for U54 Partnership Investigators, Community Advisory Panels (CAP), Research Corner, Community-based Training Program (CBTP) for Community Leaders and Stakeholders., Integrate Cancer 101 into the Stakeholders Programs, Community Engagement (CE) Training Program for Lay Community Members
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 18, 2026, 5:13 AM EDT
Active, not recruiting Phase 2 Interventional

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

NCT03228667
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
Interventions
N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
35
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 18, 2026, 5:13 AM EDT
Terminated Phase 2 Interventional

A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia

NCT03018067
View directory record Official record
Conditions
Hyperkalemia
Interventions
RDX227675, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Cary, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 18, 2026, 5:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Inhalation of 20,000 EU CCRE and Mucociliary Clearance (MCC) in Otherwise Healthy Individuals Who Are Current Cigarette Smokers

NCT00924768
View directory record Official record
Conditions
Healthy, Cigarette Smoking
Interventions
20K EU CCRE
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Oct 18, 2026, 5:13 AM EDT
Active, not recruiting Phase 2 Interventional

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
Interventions
Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1405
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 5:13 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Oral Probiotics on the Microbiome and Lipidome in Acne Vulgaris

NCT04596748
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
13 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 18, 2026, 5:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Characterize the Durability of Hypertonic Saline to Enhance Mucociliary Clearance in Healthy Subjects

NCT01617369
View directory record Official record
Conditions
Healthy Subjects
Interventions
Hypertonic Saline
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 18, 2026, 5:13 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Behavioral Studies and Practices

NCT03685292
View directory record Official record
Conditions
Behavioral
Interventions
Behavioral Advisory System, Behavioral Treatment, Behavioral Division
Behavioral · Drug · Device
Lead sponsor
Brian Bolden
Other
Eligibility
19 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 18, 2026, 5:13 AM EDT
Recruiting Not applicable Interventional

Adaptation and Examination of a Trauma-informed Intervention for Pregnant Veterans

NCT06906185
View directory record Official record
Conditions
Trauma-related Mental Health Symptoms
Interventions
Calm Moms-V, Care As Usual
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 18, 2026, 5:13 AM EDT
Recruiting Phase 2Phase 3 Interventional

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

NCT03495427
View directory record Official record
Conditions
Prostate Cancer, Recurrent Prostate Cancer
Interventions
F-DCFPyL Injection, PSMA PET
Drug · Diagnostic Test
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 18, 2026, 5:13 AM EDT
Terminated Not applicable Interventional

Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)

NCT05392855
View directory record Official record
Conditions
Cystic Fibrosis, Mucociliary Clearance Defect
Interventions
Symptom driven performance of airway clearance, Continuous daily performance of airway clearance
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 18, 2026, 5:13 AM EDT